You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.
Thromboelastography is increasingly being used by health care providers worldwide to assess the overall coagulation status of a patient. This knowledge may be especially important to health care providers in patients undergoing cardiac surgery, e.g., to risk-stratify patients prior to surgery, or to evaluate patients with bleeding complications after cardiac surgery.
The overall goal of this Request for Applications (RFA) is to advance patient care by gaining a better understanding of the role of thromboelastography as a diagnostic tool in the setting of cardiac surgical care. To this end, Haemonetics will fund Investigator-Initiated research studies that are observational in nature. These observational studies should focus on pragmatic endpoints and TEG® 6s system readouts should be obtained in parallel to conventional coagulation tests, e.g., aPPT, INR, fibrinogen, platelet count. Whereas the conventional coagulation tests will guide treatment according to the accepted standard of care, thromboelastography parameters may be used to determine the hypothetical treatment a patient would have received, had the conventional coagulation tests not been ordered. The actual and hypothetical treatments can be compared and related to patient outcomes.
Since these studies are observational in nature, they pose minimal risk to patients. This RFA only pertains to studies that fall within Haemonetics’ TEG® 6s hemostasis analyzer system’s cleared indications for use.
Examples of Research Topics
The following examples highlight research questions that, if answered, could fulfill the goals of this RFA. The application does not have to include any of these topics, and they are not meant to be all inclusive.
Review Process and Criteria
All applications will be reviewed by the Haemonetics Efficacy Studies Committee and funded based on the proposal’s clinical significance, feasibility, likelihood of success given the Principal Investigator’s (PI's) track record, environment and impact of findings on clinical care.
The RFA is supported by $250,000.00, and it is expected that 4-7 applications in the U.S. will receive funding. Funding may be used for salary support, e.g., to support a designated research fellow, and to acquire TEG® 6s global citrated multichannel cartridges. TEG® 6s analyzers will be provided free of charge for the duration of the grant support (anticipated to be 3-4 months). Since the scope between applications may vary, not all applications will be supported with the same amount of funds.
All institutions, medical centers and hospitals that provide high volume cardiac care (>500 cardiac surgeries per year) are eligible to apply.
Grant 'Thromboelastography Observational Studies in Cardiac Surgical Care’ Application Instructions
Following receipt of the letter of intent, a short 30-minute interview will be scheduled between the PI and the Haemonetics Director of Medical Affairs and Clinical Development. The purpose of the interview is primarily to answer questions the PI may have about the grant program scope, submission process and review.
Following the phone interview, the PI is encouraged to submit the following documents to the Medical Director (via email to HaemoneticsGrantsProgram@Haemonetics.com):
© 2011-2017 Haemonetics Corporation • 400 Wood Road • Braintree • MA • 02184